4 Healthcare Stock Stories for Tuesday Investment Wellness

SanofiAventis (NYSE: SNY): Current price $50.50

Sanofi and Transgene have reached a collaboration agreement for the creation of a new state-of-the-art industrial platform focused on the output of immunotherapy products including Transgene’s therapeutic products. The platform will be established on Genzyme Polyclonals site in the Lyon-Gerland area for an investment amount of €10 million equally financed by Sanofi and Transgene, but the Platform will remain Sanofi’s exclusive property.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

SNY

Onyx Pharmaceuticals (NASDAQ: ONXX): Current price $86.13

Onyx and Bayer HealthCare announced Monday that Japan’s Ministry of Health, Labor and Welfare has okayed Stivarga (regorafenib) tablets for the treatment of patients suffering from metastatic colorectal cancer. In September of 2012, Stivarga was approved by the FDA for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ONXX

Eli Lilly And Company (NYSE:LLY): Current price $56.35

Boehringer Ingelheim and Eli Lilly report that a New Drug Application for the investigational sodium glucose co-transporter-2 inhibitor empagliflozin was recently submitted to the FDA for the treatment of type 2 diabetes mellitus in adults. Empagliflozin is a mttributember of the SGLT2 inhibitor class of drugs being studied for the reduction of blood glucose levels in adults with T2D. The emerging SGLT2 inhibitor class removes excess glucose through the urine by blocking glucose re-absorption in the kidney.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

LLYPharmacyclics (NASDAQ:PCYC): Current price $79.10

The shares’ current pullback is a buying opportunity, according to Credit Suisse, considering the multi-billion dollar potential of ibrutinib. The stocks are rated Outperform along with a $90 price target.
Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.
PCYC

More Articles About:   , ,  

More from The Cheat Sheet